Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Weissenstein, Ulrike ^a   Schumann, Agnes ^b   Reif, Marcus ^b   Link, Susanne ^c   Toffol Schmidt, Ulrike D ^a   Heusser, Peter ^d  

^a Society for Cancer Research   (Switzerland)

^b Institute for Clinical Research   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN ANTIBODY; EPITHELIAL CELL ADHESION MOLECULE ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST METASTASIS; CANCER CELL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL COUNT; CELL SEPARATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; REFERENCE VALUE; RISK ASSESSMENT; SURVIVAL PREDICTION;

AGED; ANTIBODIES; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; FEMALE; HUMANS; KERATINS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84861552046     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-206     Document Type: Article

References (43)

1. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10(20):6897-6904. 10.1158/1078-0432.CCR-04-0378, 15501967.
2. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351(8):781-791. 10.1056/NEJMoa040766, 15317891.
3. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23(7):1420-1430. 10.1200/JCO.2005.08.140, 15735118.
4. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006, 12(14 Pt 1):4218-4224.
5. Liu MC, Isaacs C, Warren R, Cohen P, Wilkinson M, Ottaviano Y, Rao S, Zhang Y, Gallagher A, Shields PG. Circulating tumor cells (CTC): A reliable predictor of treatment efficacy in metastatic breast cancer (MBC). J Clin Oncol 2008, 26(May 20 suppl), abstr: 11018).
6. Nole F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, Verri E, Adamoli L, Rotmensz N, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008, 19(5):891-897. 10.1093/annonc/mdm558, 18056915.
7. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993, 82(9):2605-2610.
8. Wirtschafter A, Benninger MS, Moss TJ, Umiel T, Blazoff K, Worsham MJ. Micrometastatic tumor detection in patients with head and neck cancer: a preliminary report. Archives of Otolaryngology--Head and Neck Surgery 2002, 128(1):40-43.
9. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res 2007, 13(3):920-928. 10.1158/1078-0432.CCR-06-1695, 17289886.
10. Witzig TE, Bossy B, Kimlinger T, Roche PC, Ingle JN, Grant C, Donohue J, Suman VJ, Harrington D, Torre-Bueno J, et al. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 2002, 8(5):1085-1091.
11. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ, Gillanders WE. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004, 64(16):5818-5824. 10.1158/0008-5472.CAN-04-0754, 15313925.
12. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998, 433(2):119-129. 10.1007/s004280050226, 9737789.
13. Abd-El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004, 203(2):661-671. 10.1002/path.1559, 15141381.
14. Gusterson BA, Ross DT, Heath VJ, Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 2005, 7(4):143-148. 10.1186/bcr1041, 1175069, 15987465.
15. Deng G, Herrler M, Burgess D, Manna E, Krag D, Burke JF. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res 2008, 10(4):R69. 10.1186/bcr2131, 2575542, 18687126.
16. Rao CG, Chianese D, Doyle GV, Miller MC, Russell T, Sanders RA, Terstappen LW. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 2005, 27(1):49-57.
17. Mego M, Mani S, Li C, Andreoupolou E, Tin S, Jackson S, Cohen C, Gao H, Cristofanilli M, Reuben J. Circulating Tumor Cells (CTCs) and Epithelial Mesenchymal Transition (EMT) in Breast Cancer: Describing the Heterogeneity of Microscopic Disease. Cancer Res 2009, 69(24 Suppl). Abstract nr: 3011.
18. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S, Foekens JA. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Canc Inst 2009, 101(1):61-66.
19. Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, Curigliano G, et al. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Canc Res Treatment 2010, 122(1):211-217.
20. Fehm T, Sauerbrei W. Information from CTC measurements for metastatic breast cancer prognosis-we should do more than selecting an " optimal cut point" . Breast Canc Res Treatment 2010, 122(1):219-220.
21. Hayes DF, Ethier S, Lippman ME. New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Canc Res Treatment 2006, 100(2):237-238.
22. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol 2006, 28(2):99-105.
23. Collet D. Modelling Survival Data in Medical Research 2003, Chapman & Hall, London, UK, 2.
24. Lin DY, Wei LJ, Ying Z. Checking the Cox Model with Cumulative Sums of Martingale-Based Residuals. Biometrika 1993, 80:557-572.
25. Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data 1980, Wiley, New York.
26. Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH. Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 2005, 92(9):1767-1772. 10.1038/sj.bjc.6602519, 2362035, 15870832.
27. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009, 69(14):5627-5629. 10.1158/0008-5472.CAN-09-0654, 19584271.
28. Heatley M, Maxwell P, Whiteside C, Toner P. Cytokeratin intermediate filament expression in benign and malignant breast disease. J Clin Pathol 1995, 48(1):26-32. 10.1136/jcp.48.1.26, 502256, 7535804.
29. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J, Pantel K. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005, 11(22):8006-8014. 10.1158/1078-0432.CCR-05-0632, 16299229.
30. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Canc Res Treatment 2004, 86(3):207-213.
31. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004, 35(1):122-128. 10.1016/j.humpath.2003.08.026, 14745734.
32. Campos M, Prior C, Warleta F, Zudaire I, Ruiz-Mora J, Catena R, Calvo A, Gaforio JJ. Phenotypic and genetic characterization of circulating tumor cells by combining immunomagnetic selection and FICTION techniques. J Histochem Cytochem 2008, 56(7):667-675. 10.1369/jhc.2008.951111, 2430160, 18413646.
33. Gaforio JJ, Serrano MJ, Sanchez-Rovira P, Sirvent A, Delgado-Rodriguez M, Campos M, de la Torre N, Algarra I, Duenas R, Lozano A. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer 2003, 107(6):984-990. 10.1002/ijc.11479, 14601059.
34. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 1998, 95(8):4589-4594. 10.1073/pnas.95.8.4589, 22534, 9539782.
35. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad T, Diel I, Solomayer E-F, Theocharous P, Coombes RC, Smith BM, Wunder E, Marolleau J-P, Garcia J, Pantel K. Standardization of the Immunocytochemical Detection of Cancer Cells in BM and Blood: I. Establishment of Objective Criteria for the Evaluation of Immunostained Cells. Cytotherapy 1999, 1(5):377-388. 10.1080/0032472031000141283, 20426539.
36. Tibbe AG, Miller MC, Terstappen LW. Statistical considerations for enumeration of circulating tumor cells. Cytometry A 2007, 71(3):154-162.
37. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005, 11(10):3678-3685. 10.1158/1078-0432.CCR-04-2469, 15897564.
38. de Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 2010, 21(1):33-39. 10.1093/annonc/mdp262, 19602564.
39. Thalgott MK, Nawroth R, Andergassen U, Rack BK, Maurer T, Heck M, Kübler H, Gschwend JE, Retz M. Detection of circulating tumor cells (CTC) with the Cell Search system in patients with prostate cancer. Genitourinary Cancers Symposium 2010, Abstract. No.: 239.
40. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007, 13(23):7053-7058. 10.1158/1078-0432.CCR-07-1506, 18056182.
41. Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, Koscuiszka M, Vaananen RM, Pettersson K, Chun FK, et al. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with Cell Search assay and association with bone metastases and with survival. Clin Chem 2009, 55(4):765-773. 10.1373/clinchem.2008.117952, 2782624, 19233911.
42. Milowsky MI, Ishill NM, Riches J, Fleisher M, Trout A, Valentini A, Boyle MG, Bajorin DF. Circulating tumor cells in patients with metastatic urothelial cancer. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2008, 26(15S (May 20 Supplement)):16054. © 12008 American Society of Clinical Oncology.
43. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009, 27(21):3437-3444. 10.1200/JCO.2008.18.9068, 2717751, 19470939.